Adverse reactions with DMSO-cryopreserved stem cell infusion are well-recognized. However, severe, lifethreatening anaphylactic reactions with DMSO are very rarely described in the literature. We report here a 58-year-old female with AL amyloidosis who developed an unexpected episode of respiratory arrest a few seconds after the beginning of thawed stem cell product infusion. Fortunately, the patient was resuscitated successfully without the need for intubation. The prompt development of the reaction just a few seconds after the stem cell infusion convincingly implicates DMSO as the potential suspect. The presence of amyloid cardiomyopathy might have also contributed to this adverse event. Bone Marrow Transplantation (2000) 25, 1299-1301. Keywords: DMSO; respiratory depression; stem cell transplantation; amyloidosis Amyloid light-chain (AL) amyloidosis is now recognized as a plasma cell dyscrasia resulting from the synthesis and deposition of insoluble immunoglobulin light chains in various organ systems.
Amyloid light-chain (AL) amyloidosis is now recognized as a plasma cell dyscrasia resulting from the synthesis and deposition of insoluble immunoglobulin light chains in various organ systems. 1 Heart involvement has been associated with increased mortality and poorer prognosis. 1, 2 The conventional alkylating agent-based therapy of AL amyloidosis has been generally unsuccessful with an average overall survival of 12-20 months, and 6 months in patients with cardiac involvement.
1 Dose-intensive melphalan with autologous peripheral blood stem cell rescue (APBSCT) has been recently demonstrated to be an effective treatment modality, [3] [4] [5] [6] although follow-up is still short-term. 3 However, the early mortality within the first 100 days can be high (up to an average of 30%) mostly due to heart failure associated with amyloid cardiomyopathy. 4, 5 Dimethylsulphoxide (DMSO) prevents damage to hemopoietic stem cells during cryopreservation.
7 DMSO-cryopreserved autologous stem cell infusions have been reported to cause a wide variety of toxicities which have been mostly mild. 8, 9 Life-threatening anaphylaxis-like reac- tion is very rare and has been reported only in isolated cases. [10] [11] [12] [13] [14] We present here a patient with AL amyloidosis and cardiac involvement who developed acute respiratory arrest which was reversed successfully with prompt intervention.
Case report
A 58-year-old woman presented to another center with bilateral lower extremity edema and fatigue. She was found to have hypoalbuminemia and a nephrotic range proteinuria. A computerized tomography of the abdomen showed a diffusely enlarged liver and bilaterally enlarged kidneys. An electrocardiogram (EKG) revealed first degree AV block and low voltaged QRS waves in leads II, III and aVF and ST segment elevation in V 1 and V 2 and T inversion in V 3 to V 6 . An echocardiogram was obtained which showed mild left ventricular hypertrophy with a normal ejection fraction of 55%. The patient subsequently underwent a kidney biopsy which revealed sclerosis and obsolescence of several glomeruli with accumulation of Congo-red positive eosinophilic material within the mesangium and the glomerular capillary walls. Lambda light chains were stained only in the glomeruli and blood vessels by immunofluorescence. The patient was referred to our center for a possible APBSCT with the diagnosis of ALtype amyloidosis.
On physical examination, the patient was normotensive. She had a grade 3-4/6 holosystolic murmur, a hepatomegaly palpable 3 cm below the left costal margin and 2+ pitting edema in both lower extremities. A complete blood count was normal except for a hemoglobin of 10.1 g/dl. Blood chemistry was remarkable for a BUN of 50 mg/dl, creatinine 2.4 mg/dl, total protein 5.0 g/dl, albumin 2.4 g/dl, and AST 58 IU/l. A 24h urine electrophoresis showed a total protein of 5.9 g/day with no abnormal protein bands. Serum protein electrophoresis identified no paraprotein band. Bone marrow biopsy revealed 5% plasma cells.
After the completion of routine transplant work-up and collection of stem cells after G-CSF mobilization, the patient was treated with intermediate-dose melphalan 50 mg/m 2 on days −3 and −2 for conditioning, since she was not a suitable candidate for dose-intensive melphalan therapy as previously described. 6 On day 0, stem cells were thawed and infused after premedication with 25 mg diphenhydramine, 50 mg hydrocortisone and 500 mg calcium gluconate. Seconds after the start of infusion, the patient developed acute restlessness, fixed stare, and subsequent respiratory depression leading to a complete arrest with no spontaneous respiration. Oxygen saturation dropped and she became completely unresponsive. The heart rate remained regular without any arrhythmia, although the rate dropped to 60/min. The infusion of stem cells was stopped immediately and the product sent back to the stem cell laboratory. She was resuscitated successfully with artificial respiration and 100% oxygen, intravenous steroids and fluids without the need for intubation. Her EKG remained unchanged. All stem cell products were washed for the removal of DMSO preservative and reinfused later that day using higher doses of premedications without any complication. The patient is currently doing well with a good response on day 139 following transplantation.
Discussion
DMSO is a universal cryoprotective solvent used for the preservation and storage of hematopoietic progenitor/stem cells due to its ability to preclude damage to living cells during cryopreservation and thawing. 7 Toxicity associated with the infusion of DMSO-cryopreserved autologous bone marrow grafts has been well recognized. 8, 9 These toxicities have traditionally been attributed to the infusion of products of damaged cell lysis, complement activation, large volumes or DMSO itself. Temporary hypo-or hypertension, bradycardia, bradypnea, chest tightness, and dyspnea have all been reported, but severe, life-threatening respiratory depression is very rare. [10] [11] [12] [13] [14] Furthermore, none of the reported reactions was associated with respiratory arrest due to an anaphylaxis-like episode just at the beginning of the infusion of thawed stem cell graft. Only one report described an anaphylactic reaction-like picture with cardiac and respiratory arrest after completion of the infusion. 14 Another report described a similar reaction among 82 patients, but the details of the reaction were not given. 9 Additionally, there remains also the possibility that severe adverse reactions might have been under-reported. Lifethreatening complications, in fact, may be more frequent in reality than anticipated.
The exact reason for respiratory failure is not clear. DMSO was reported to increase cardiac index, stroke volume, and pulmonary systolic, mean, diastolic and pulmonary capillary wedge pressures immediately after the infusion. A significant decrease in systemic vascular resistance was also observed. 15 One might argue that the patient's underlying disease with cardiovascular compromise might have contributed to this unexpected adverse event. 2 The existence of baseline amyloid cardiac involvement might have rendered the patient more susceptible to the DMSO product. However, this does not seem likely given the nature and timing of the reaction. We presume that this reaction was most probably due to the release of histamine or other mediators of anaphylaxis and mast cell degranulation mediated by DMSO, 16 rather than lysis products of marrow infusion, since the reaction occurred just after the beginning of stem cell infusion independent of the infused DMSO volume. A vagal reaction due to low temperature of the infused stem cell product or bacterial contamination are other possible causes. However, hypoxia is usually not associated with vasovagal reaction. The absence of fever and sterile cultures of the stem cell sample at the time of collection 1 week before the day of infusion make a bacterial contamination highly unlikely.
Because cardiac amyloid patients are at high risk for the graft infusion-related reactions, maximum effort should be made to prevent and interfere with these complications. We recommend that the stem cell product be washed prior to infusion to deplete the graft of DMSO. Prefilled epinephrine and steroid syringes and necessary equipment for a possible intubation should be kept ready during stem cell infusion at the bedside for prompt intervention. Because the episodes might be idiosyncratic and can not be predicted, close supervision and careful monitorization of the patients are mandatory.
